Back to Results
First PageMeta Content
Antifungals / Yeasts / Fungal diseases / Echinocandins / Pfizer / Candida krusei / Fungemia / Candidiasis / Anidulafungin / Biology / Mycology / Microbiology


Rationale for the EUCAST clinical breakpoints
Add to Reading List

Document Date: 2011-05-04 15:48:53


Open Document

File Size: 170,61 KB

Share Result on Facebook

Company

J Clin Pharm / /

Continent

Europe / /

Country

Germany / Switzerland / Norway / Turkey / France / Austria / Netherlands / Italy / Sweden / Finland / Spain / Greece / Denmark / /

IndustryTerm

anidulafungin / /

MedicalCondition

HIV / deep-seated organ infection / human infections / Clinical data Invasive candidiasis / neutropenia / candidiasis / abscesses / invasive candidiasis / deep-seeded organ infection / breakthrough infections / /

MedicalTreatment

intravenous therapy / /

Organization

European Society for Clinical Microbiology and Infectious Diseases / EUCAST MIC / European Centre for Disease Prevention and Control / European Society for Clinical Microbiology / European Committee on Antimicrobial Susceptibility Testing / Infectious Diseases / not been determined using EUCAST / /

Person

Candida krusei / Candida glabrata / /

Position

NA NA General / /

Product

fluconazole / /

Technology

Pharmacokinetics / Pharmacodynamics / /

URL

http /

SocialTag